Brief: Cantargia Presents New Preclinical Data

Cantargia AB

10/05/2021 14:05

May 10 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA PRESENTS NEW PRECLINICAL DATA SHOWING UNIQUE
IMPROVEMENT OF HEART FUNCTION IN MYOCARDITIS USING ANTIBODY
CAN10
    * DATA DEMONSTRATE THAT INTERLEUKIN-1 RECEPTOR ACCESSORY
PROTEIN
(IL1RAP)-BINDING ANTIBODY CAN10 REDUCES INFLAMMATION AND/OR
FIBROSIS IN SEVERAL DISEASE MODELS INCLUDING MYOCARDITIS
    * CAN10, WHICH BLOCKS SIGNALING OF IL-1, IL-33 AND IL-36,
COUNTERACTED DETERIORATION OF CARDIAC FUNCTION MORE POTENTLY
THAN BLOCKADE OF IL-1 SIGNALING ONLY
    * RESULTS SUGGEST POTENT CLINICAL EFFECT CAN BE ACHIEVED IN
INFLAMMATORY DISEASE BY SIMULTANEOUS BLOCKADE OF IL-1, IL-33 AND
IL-36 WITH CAN10

Source text for Eikon:  ID:nWkr3VBsRK 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))